公开(公告)号：US20210290595A1

公开(公告)日：2021-09-23

申请号：US17200146

申请日：2021-03-12

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université Nice Sophia Antipolis ,  Centre National de la Recherche Scientifique (CNRS)

发明人： Patrick COLLOMBAT ,  Tiziana NAPOLITANO ,  Fabio AVOLIO

IPC分类号： A61K31/415 ,  A61P3/10 ,  C12N15/113

摘要： The present invention relates to methods and pharmaceutical compositions useful for the treatment of hyperglycemia. Thorough multiple analyses, inventors demonstrated that Gfi1 is expressed in pancreatic acinar cells, starting from the first stages of pancreatic embryonic development. Furthermore, they observed that Gfi1 mRNA levels remain steady throughout embryonic development, while they significantly increase during the first days of life. They challenged conditional mutant mice with high fat diet for 5 months and monitored their weight and glycemia weekly. All the animals displayed a rapid increase in body mass as expected. While control mice rapidly developed a massive hyperglycemia, mutant mice remained normoglycemic throughout the entire experiment. A similar protection from induced diabetes was observed upon treatment with a high dose of Streptozotocin. Accordingly, the present invention relates to a method of treating hyperglycemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of Gfi1.

公开(公告)号：US20200030292A1

公开(公告)日：2020-01-30

申请号：US16496761

申请日：2018-03-26

申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Université Nice Sophia Antipolis ,  Centre National de la Recherche Scientifique (CNRS)

发明人： Patrick COLLOMBAT ,  Tiziana NAPOLITANO ,  Fabio AVOLIO

IPC分类号： A61K31/415 ,  C12N15/113 ,  A61P3/10

摘要： The present invention relates to methods and pharmaceutical compositions useful for the treatment of hyperglycemia. Thorough multiple analyses, inventors demonstrated that Gfi1 is expressed in pancreatic acinar cells, starting from the first stages of pancreatic embryonic development. Furthermore, they observed that Gfi1 mRNA levels remain steady throughout embryonic development, while they significantly increase during the first days of life. They challenged conditional mutant mice with high fat diet for 5 months and monitored their weight and glycemia weekly. All the animals displayed a rapid increase in body mass as expected. While control mice rapidly developed a massive hyperglycemia, mutant mice remained normoglycemic throughout the entire experiment. A similar protection from induced diabetes was observed upon treatment with a high dose of Streptozotocin. Accordingly, the present invention relates to a method of treating hyperglycemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of Gfi1.

公开(公告)号：US20230340044A1

公开(公告)日：2023-10-26

申请号：US18156865

申请日：2023-01-19

申请人： DIOGENX ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  UNIVERSITÉ CÔTE D'AZUR ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： Patrick COLLOMBAT ,  Paolo BOTTI

IPC分类号： C07K14/47 ,  A61P3/10 ,  C12N15/63

CPC分类号： C07K14/4705 ,  A61P3/10 ,  C12N15/63 ,  C07K2319/30

摘要： The present invention relates to recombinant variants of R-spondin proteins and their use as a medicament, in particular for the treatment of diabetes.